{"result": {"id": "chatcmpl-488", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "**Bevacizumab** is a monoclonal antibody that acts as an anti-angiogenic drug. It suppresses VEGFR-2 mRNA levels, making it effective in treating various conditions. Specifically, Bevacizumab is used to treat certain cancers and eye diseases such as myopic choroidal neovascularization (mCNV).  It's also approved for cancer treatment and is commonly administered through anti-VEGF injections. \n\nBevacizumab is an anti-VEGF antibody classified as an anti-angiogenesis inhibitor. It works by blocking vascular endothelial growth factor (VEGF), which plays a crucial role in angiogenesis, the formation of new blood vessels. This drug inhibits the growth of new blood vessels and has been used to treat various conditions, including non-small cell lung cancer (NSCLC) and osteosarcoma. Bevacizumab is also used in anti-angiogenic therapies targeting the VEGF pathway for treating cancers and certain eye diseases like vascular leakage. It has potential applications in treating corneal neovascularization and other conditions.  It is an antitumorigenic drug. \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743240740, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 221, "prompt_tokens": 369, "total_tokens": 590, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"BEVACIZUMAB\"\nDescription List: [\"**Bevacizumab** is a monoclonal antibody that acts as an anti-angiogenic drug. It suppresses VEGFR-2 mRNA levels, making it effective in treating various conditions.  Specifically, Bevacizumab is used to treat certain cancers and eye diseases such as myopic choroidal neovascularization (mCNV). It's also approved for cancer treatment and is commonly administered through anti-VEGF injections. \\n\", \"**Bevacizumab** is an anti-VEGF antibody classified as an anti-angiogenesis inhibitor.  It works by blocking vascular endothelial growth factor (VEGF), which plays a crucial role in angiogenesis, the formation of new blood vessels. This drug inhibits the growth of new blood vessels and has been used to treat various conditions, including non-small cell lung cancer (NSCLC) and osteosarcoma. Bevacizumab is also used in anti-angiogenic therapies targeting the VEGF pathway for treating cancers and certain eye diseases like vascular leakage. It has potential applications in treating corneal neovascularization and other conditions.  It is an antitumorigenic drug. \\n\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_d959096d783d7b08a57dc953f36854aff356e23c1c4fbb18d99f62efff26c492_v2"}